Background: Adiponectin has been found to be associated with the pathogenesis of diabetes, obesity and some cardiovascular diseases, which usually coexist with obstructive sleep apnea hypopnea syndrome (OSAHS). However, an association between adiponectin and OSAHS has rarely been reported. Objectives: To investigate the levels of serum adiponectin in adult male patients with OSAHS. Methods: Following polysomnographic examination, 86 adult male habitual snorers were divided into simple snorers (control group) and OSAHS patients (OSAHS group) who were further divided into mild, moderateandsevere OSAHS subgroups based on their apnea hypopnea index (AHI). There was no significant difference in age, body mass index (BMI), fasting blood glucose (FBG) and insulin resistance expressed as homeostasis model assessment (HOMA) between the two groups. The serum adiponectin levels were measured by radioimmunoassay. Results: Serum adiponectin levels were significantly lower in the OSAHS group than in the control (p< 0.01). Such a decrease in adiponectin level was most significant in patients with moderate and severe OSAHS. Pearson correlation analysis showed that in OSAHS patients, serum adiponectin level was negatively correlated with BMI, waist (WC) and neck (NC) circumferences, AHI and HOMA, but positively correlated with nadir pulse oxyhemoglobin saturation (nadir SpO2). After controlling for HOMA, BMI, NC and WC in OSAHS patients, a partial correlation analysis showed that adiponectin levels were negatively correlated with AHI but positively correlated with nadir SpO2. Multiple logistic regression analysis indicated that adiponectin was independently associated with OSAHS. Conclusions: Serum adiponectin levels were significantly lower in OSAHS patients than in simple snorers. OSAHS may cause a decrease in serum adiponectin level.

Keywords:
Obstructive sleep apnea hypopnea syndrome, Adiponectin, Apnea hypopnea index
1.
Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29–33.
2.
Holst D, Grimaldi PA: New factors in the regulation of adipose differentiation and metabolism. Curr Opin Lipidol 2002;13:241–245.
3.
Harsch IA, Schahin SP, Bruckner K, Radespiel-Troger M, Fuchs FS, Hahn EG, Konturek PC, Lohmann T, Ficker JH: The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnea syndrome and type 2 diabetes. Respiration 2004;71:252–259.
4.
Harsch IA: Adiponectin in patients with obstructive sleep apnea syndrome: Course and physiological relevance. Respiration 2004;71:580–588.
5.
American Academy of Sleep Medicine Task Force: Sleep-related breathing disorders in adults: Recommendations for syndrome definition and measurement techniques in clinical research. Sleep 1999;22:667–689.
6.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner KC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
7.
Vionnet N, Hani EH, Dupont S, Gallina S, Francke S, Dotte S, De-Matos F, Durand E, Lepretre F, Lecoeur C, Gallina P, Zekiri L, Dina C, Froguel P: Genomewide search for type 2 diabetes-susceptibility genes in French whites: Evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome lq21-q24. Am J Hum Genet 2000;67:1470–1480.
8.
Iwashima Y, Katsuya T, Isikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi H, Matsuzawa Y, Ogihara T: Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004;43:1318–1323.
9.
Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: Adipocyte derived protein adiponectin. Circulation 1999;100:2473–2476.
10.
Delporte ML, Funahashi T, Takahashi M, Matsuzawa Y, Brichard SM: Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: In vitro and in vivo studies. Biochem J 2002;367:677–685.
11.
Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R: Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS 2001;507:142–146.
12.
Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Hirano T, Adachi M: Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003;107:1129–1134.
13.
Hatipoglu U, Rubinstein I: Inflammation and obstructive sleep apnea syndrome pathogenesis: A working hypothesis. Respiration 2003;70:665–671.
14.
Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R: Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1. adipocytes. Biochem Biophys Res Commun 2003;301:1045–1050.
15.
Chen DM: Products of adipocytes and obesity and metabolic syndrome. Chin J Endocrinol Metab 2003;19:161–163.
16.
Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R: Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002;290:1084–1089.
17.
Palmer L, Redline Susan: genomic approaches to understanding obstructive sleep apnea. Respir Physiol Neurobiol 2003;135:187–205.
18.
Patel S, Palmer L, Larktin E, Jenny NS, White D, Redline S: Relationship between obstructive sleep apnea and diurnal leptin rhythms. Sleep 2004;27:235–239.
19.
Matsubara M, Maruoka S, Katayose S: Inverse relationship between plasma adiponectin and leptin concentrations in normal weight and obese women. Eur J Endocrinol 2002;147:173–180.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.